Your browser doesn't support javascript.
Cutaneous manifestations following COVID-19 vaccination: A report of 25 cases.
Shakoei, Safoura; Kalantari, Yasamin; Nasimi, Maryam; Tootoonchi, Nasim; Ansari, Mahshid Sadat; Razavi, Zahra; Etesami, Ifa.
  • Shakoei S; Department of Dermatology, Imam Khomeini Hospital, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
  • Kalantari Y; Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Nasimi M; Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Tootoonchi N; Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Ansari MS; Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Razavi Z; Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Etesami I; Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Dermatol Ther ; 35(8): e15651, 2022 08.
Article in English | MEDLINE | ID: covidwho-1895974
ABSTRACT
Various adverse effects particularly cutaneous manifestations associated with different COVID-19 vaccines have been observed in practice. The aim of our study was to evaluate all patients who presented to our tertiary center with skin manifestations following COVID-19 vaccines injection from September to December 2021. All patients with skin manifestation within 30 days or less following COVID-19 vaccination were enrolled in our case-series. All cases included in our study were diagnosed based on clinical and/or histopathological evaluation and all other possible differential diagnoses were ruled out. Twenty-five individuals including 16 (64%) males and 9 (36%) females with the mean age of 47 ± 17.62 years (range 18-91) were enrolled in our study. Twenty-two (88%) patients developed lesions after Sinopharm vaccine injection and 3 (12%) cases manifested lesions after the AstraZeneca vaccine. Six (24%) patients developed new-onset lichen planus (LP) and 1 (4%) patient manifested LP flare-up. Two (8%) individuals developed psoriasis and 1 (4%) case showed psoriasis exacerbation. One (4%) patient developed new-onset pemphigus vulgaris (PV) and 1 (4%) case experienced a flare of PV lesions. One (4%) patient manifested pityriasis lichenoides et varioliformis acuta (PLEVA) flare-up. Other new-onset cases were as follows toxic epidermal necrolysis (TEN) (n = 1, 4%), bullous pemphigoid (BP) (n = 2, 8%), alopecia areata (AA) (n = 2, 8%), pytriasis rosea (n = 1, 4%), herpes zoster (n = 1, 4%), cutaneous small vessel vasculitis (n = 1, 4%), erythema multiform (EM) and urticaria (n = 3, 12%), and morphea (n = 1, 4%). Physicians should be aware of the possible side effects especially cutaneous manifestations associated with COVID-19 vaccines.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Psoriasis / Pemphigus / Pityriasis Lichenoides / COVID-19 Vaccines / COVID-19 Type of study: Case report / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Dermatol Ther Journal subject: Dermatology Year: 2022 Document Type: Article Affiliation country: Dth.15651

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Psoriasis / Pemphigus / Pityriasis Lichenoides / COVID-19 Vaccines / COVID-19 Type of study: Case report / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Dermatol Ther Journal subject: Dermatology Year: 2022 Document Type: Article Affiliation country: Dth.15651